Cosomil develops high-sensitivity diagnostic technology based on single-molecule enzyme activity measurement using liquid biopsy techniques. This platform enables the precise evaluation of various enzyme activities in blood samples for advanced diagnostics. The company focuses on early disease diagnosis drug development and pharmaceutical support services, particularly targeting early detection of pancreatic cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for detecting diseases like pancreatic cancer often lack the sensitivity needed for early diagnosis, leading to delayed treatment and poorer patient outcomes. Traditional biopsies are invasive and may not be feasible for all patients or disease stages. Existing liquid biopsy techniques may not provide sufficient resolution to detect subtle changes in enzyme activity indicative of early-stage disease.
Solution
The company has developed a liquid biopsy technology based on single-molecule enzyme activity profiling, enabling ultra-sensitive detection of enzyme activity at the individual molecule level. This approach allows for the early and accurate diagnosis of diseases by identifying subtle changes in enzyme activity in a patient's blood sample. The technology utilizes fluorescent enzyme substrates and microdevices to quantify enzyme activity with high precision. By detecting these changes earlier than traditional methods, the technology aims to improve patient outcomes through timely intervention and treatment.
Target Audience
The primary target audience includes healthcare providers and diagnostic companies focused on early disease detection, as well as pharmaceutical companies involved in drug development and biomarker discovery.
Features
- Single-molecule enzyme activity measurement for ultra-high sensitivity
- Liquid biopsy approach for non-invasive disease detection
- Utilizes fluorescent enzyme substrates and microdevices for precise quantification
- Technology applicable to early diagnosis of diseases, including pancreatic cancer
- Supports drug development efforts by providing a sensitive biomarker detection platform